. (2023). Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study. Bmj Open Diabetes Res Care, 11. http://doi.org/10.1136/bmjdrc-2023-003550
UK data driving real-world evidence